OMSB Selection ExamSign in

Curriculum · ENT, Ophthalmology, and Dermatology

Vitiligo

What it is

Vitiligo is an autoimmune condition which results in the loss of melanocytes and consequent depigmentation of the skin. Put the other way, it is an acquired partial to complete loss of pigmentation due to autoimmune destruction of melanocytes. It is thought to affect around 1% of the population, and symptoms typically develop by the age of 20-30 years.

The distribution pattern of the amelanotic skin lesions divides into two families:

The buzzword to carry into an exam is chalk-white patches on the hands and face, or depigmented patches.

The autoimmune company it keeps

Because the destruction of melanocytes is autoimmune, vitiligo is associated with other autoimmune disorders, and the association is asked about more often than the skin itself. The core list is type 1 diabetes mellitus, Addison's disease, autoimmune thyroid disorders, pernicious anaemia and alopecia areata; Hashimoto thyroiditis is the thyroid disorder named by name, and Graves disease is named too.

The cluster runs wider than the dermatology page, because autoimmune diseases tend to cluster:

Trauma may precipitate new lesions, which is the Koebner phenomenon, also called the isomorphic response. The clinical entities that commonly display it are psoriasis, vitiligo, lichen planus, lichen niditus, cutaneous small vessel vasculitis and Still disease. It is to be distinguished from autoinoculation, the pseudo-Koebner phenomenon seen with verrucae or mollusca, and from the Wolf isotopic response, where a second skin disease appears at the site of an earlier unrelated and often healed skin disease.